ArticleFrontiers in cellular and infection microbiology2026
N-myc and STAT interactor is a novel biomarker for predicting the severity and clinical outcome of sepsis: a prospective research.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- N-myc and STAT interactor promotes poly(I:C)-induced pulmonary coagulopathy via STAT3-dependent tissue factor.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is prevalent and life-threatening condition that is often associated with high mortality rates. Early stratification is significantly associated with prognosis. Traditional biomarkers show low specificity, while scoring systems are time-consuming. This study aimed to evaluate the predictive value of a novel biomarker (N-myc and STAT interactor (NMI)) in assessing disease severity and clinical outcome in sepsis. Methods: A total of 399 adult patients diagnosed with sepsis were recruited. The least absolute shrinkage and selection operator (LASSO), logistic regression analysis, and receiver operating characteristic curve (ROC) were used to prove the predictive value of NMI in serum for disease severity (septic shock) and clinical outcome (30-day mortality) in the training set (n = 302). Internal validation (n = 97) was utilized to guarantee the stability of the findings. Results: The study revealed that NMI was independently associated with 30-day mortality and the occurrence of septic shock through LASSO and logistic analysis. The NMI concentrations of patients with septic shock (166.1 [98.8, 437.5]) and non-survivors (208.7 [113.5, 809.6]) were higher than those of sepsis patients (54.2 [45.4, 64.8]) and survivors (59.3 [48.0, 90.2]), respectively. The area under the curve (AUC) of NMI for predicting mortality and septic shock was 0.86 and 0.92, respectively, which significantly outperformed other biomarkers and scoring systems. The AUCs of new scoring systems containing NMI were all remarkably higher than the original scoring systems (APACHE II, SOFA, qSOFA) for the prediction of clinical outcome and disease severity. Stratification of NMI concentrations in Kaplan-Meier survival curves proved the 30-day survival rate decreased with the increasing level of NMI ( Conclusions: Serum NMI can serve as a novel parameter to predict the severity and clinical outcome of sepsis, potentially facilitating timely disease stratification and providing certain guidance for clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.